Pliant Therapeutics Inc（PLRX）财务数据PLRXPliant Therapeutics Inc

Evaluating the bottom line, Pliant Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -50.29%, provide a clear picture of how effectively PLRX converts its operational activities into shareholder value.

In the context of the broader market, PLRX competes directly with industry leaders such as CSBR and XBIT. With a market capitalization of $71.21M, it holds a leading position in the sector. When comparing efficiency, PLRX's gross margin of N/A stands against CSBR's 50.78% and XBIT's N/A. Such benchmarking helps identify whether Pliant Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Pliant Therapeutics has reported negative net income for several quarters, with the most recent figures showing a net loss of -$22.37 million for Q2 2026. The company's current ratio is strong at 9.90, indicating good short-term liquidity, but the overall financial performance is concerning due to continuous losses.